Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of STING-TRIM29 interaction inhibitor SB24011 on gene expression upon solo or co-treatment with STING agonist in Raw264.7 murine macrophage-like cells.

ABSTRACT: Effect of STING-TRIM29 interaction inhibitor SB24011 on gene expression upon solo or co-treatment with STING agonist in Raw264.7 murine macrophage-like cells.

PROVIDER: PRJNA854386 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Effect of STING-TRIM29 interaction inhibitor SB24011 on gene expression upon solo or co-treatment with STING agonist in Raw264.7 murine macrophage-like cells.

Project description:SB24011 upregulates cellular STING levels through inhibition of STING-TRIM29 E3 ligase interaction. We performed gene expression profiling using RNA-seq in Raw264.7 cells, to investigate the effect of SB24011 on 1) STING downstream pathways upon combination with cGAMP, or 2) the novel gene expressions upon STING upregulation by SB24011.

2025-06-28 | GSE207257 | GEO

Human Breast Cells: Control vs. TRIM29 cDNA- or TRIM29 shRNA-transfected

Project description:Transcriptional profiling of human normal-like breast cells MCF10A comparing control MCF10A cells transfected with a pLenti6/BLOCK-iT™-DEST vector with MCF10A cells transfected with a pLenti6/BLOCK-iT™-DEST vector containing TRIM29 shRNA targeting nucleotides 1265–1285 of the TRIM29 open reading frame (ORF, NM_012101). Transcriptional profiling of human breast cancer cells MCF7 comparing control MCF7 cells transfected with a pLenti6.2/N-LumioTM/V5-DEST vector with MCF7 cells transfected with a pLenti6.2/N-LumioTM/V5-DEST vector containing TRIM29 full-length cDNA (ORF, NM_012101). Two-condition experiment, MCF10A-vector control vs. MCF10A-TRIM29 shRNA cells; MCF7-vector control vs. MCF7-TRIM29 cells.

2010-12-23 | E-GEOD-26238 | biostudies-arrayexpress

Transcriptome-wide identification of STING agonist programed B cells

Project description:We employed RNA-seq to study the transcriptomic change in B lymphocytes in response to STING agonist. Transcriptomic analysis of wild type and TMEM173–/– B cells stimulated with STING agonist revealed that the inflammatory response pathway enriched in 3'3'-cGAMP treated WT B cells but lacking in Tmem173-/-B cells comprised of a cluster containing inhibitory regulators, provoking STING signal to evade immune surveillance by inducing an immunosuppressive B cell population.

2022-08-10 | GSE199343 | GEO

Human Breast Cells: Control vs. TRIM29 cDNA- or TRIM29 shRNA-transfected

2010-12-23 | GSE26238 | GEO

Combination of EZH2 inhibitor and STING agonist in melanoma cell lines

Project description:In order to better understand the effects of combination treatment with EZH2 inhibitor and STING agonist in human melanoma cells, RNA sequencing was performed to explore transcriptome alteration.

2021-10-10 | GSE171538 | GEO

DMXAA (STING agonist) efficacy on tumor microenvironment after CAR-T therapy

Project description:This study is designed to uncover the mechanism by which STING agonist (DMXAA) changes the tumor microenivorment of mammary tumor to support Th/Tc17 CAR-T cells treatment.

2020-11-25 | GSE162073 | GEO

A Phosphotriester-Masked Dideoxy-cGAMP Derivative as a Cell-Permeable STING Agonist

Project description:2’3’-cyclic GMP-AMP (cGAMP) is a cyclic dinucleotide second messenger in which guanosine and adenosine are connected by one 3’-5’ and one 2’-5’ phosphodiester linkage. It is formed in the cytosol upon detection of pathogenic DNA by the enzyme guanosine-monophosphate-adenosine monophosphate synthase (cGAS). cGAMP subsequently binds to the adaptor protein stimulator of interferon genes (STING) to elicit an innate immune response leading to the production of type I interferons and cytokines. STING agonists are a highly promising avenue for an immuno-oncological anticancer therapy. A particular challenge with cyclic dinucleotide STING agonists are the two negative charges of the phosphodiester linkages, which strongly reduce the ability of such compounds to penetrate cell membranes. The development of cell-permeable STING agonists that can stimulate the immune system to enhance their anticancer potency is currently of utmost importance in the field. Here, we report the development of a dideoxy derivative of cGAMP as a phosphotriester prodrug, where the negative charge of the phosphate backbone has been masked with a thioester. We found that this thioester-protected compound features a dramatic increase in its cellular potency that rises from EC50 = 5 µM to 25 nM. The new compound is envisioned to enable an efficient STING-agonist-based anticancer therapy.

2025-05-07 | PXD057395 | Pride

A novel rexinoid agonist, UAB116, decreases metastatic phenotype in hepatoblastoma by inhibiting the Wnt/β-catenin pathway via upregulation of TRIM29

Project description:Hepatoblastoma (HB) is the most common pediatric primary liver tumor. About 20% of children have pulmonary metastasis at presentation. Survival rates for these children are dismal, not exceeding 25%. To study this subset of the HB population, we sequenced a metastatic HB cell line, HLM_2, and identified a downregulation in the liver X receptor (LXR)/rexinoid X receptor (RXR) pathway. LXR/RXRs are transcriptional regulators of genes involved in HB carcinogenesis including the Wnt/β-catenin signaling pathway. We assessed the effects of a novel LXR/RXR agonist, UAB116, on metastatic HB, hypothesizing that this compound would affect genes governing the Wnt/β-catenin pathway, leading to decreased metastatic phenotype in HLM_2 metastatic HB cells. We evaluated the effects on viability, proliferation, stemness, clonogenicity, and motility, and performed RNA sequencing to study differential gene regulation. Treatment with UAB116 (0-50 µM) for 72 hours decreased HLM_2 proliferation, stemness, clonogenicity, and invasion. RNA sequencing identified an 8-fold increase in TRIM29, a gene known to inhibit β-catenin, in cells treated with UAB116. These results show that treatment with an LXR/RXR agonist, UAB116, decreases metastatic HB cell proliferation, stemness, and invasion, likely through upregulation of TRIM29, a known regulator of the Wnt/β-catenin pathway, providing support for further exploration of LXR/RXR agonism as a therapeutic strategy for metastatic HB.

2025-05-22 | GSE290638 | GEO

Solo specimen

Project description:Solo specimen Raw sequence reads

| PRJNA1114439 | ENA

PSC co-culture STING modulation 167 samples bulk RNA-seq

Project description:Bulk RNAseq of pancreatic stellate cells (PSC) and tumour cells treated with STING agonist DMXAA, STING inhibitor H151 or DMSO control. PSC were cultured alone as mono-cultures or in co-culture with mouse tumour organoids, The PSC and tumour cells were recovered by FACS using fluorecent proteins mKate-2 and tGFP, respectively.

2025-03-19 | E-MTAB-14946 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data